U.S. pharma giant copyright scrapped two experimental weight loss drugs final year—a the moment-daily capsule, lotiglipron, as a result of elevated liver enzymes as well as a two times-each day tablet, danuglipron, resulting from robust Uncomfortable side effects—but CEO Albert Bourla has explained the company is set to “Enjoy and gain” in